You are here: Welcome to the MPKB » Welcome to the MPKB » Resources for physicians » Physicians' concerns about the Marshall Protocol
Home

Differences

This shows you the differences between two versions of the page.

Link to this comparison view

Both sides previous revisionPrevious revision
Next revision		Previous revision
home:physicians:concerns [02.09.2019] – [Concerns about lack of clinical evidence] sallieqhome:physicians:concerns [07.13.2019] – [Concerns about immunopathology] sallieq
Line 1: Line 1:
 ====== Physicians' concerns about the Marshall Protocol ====== ====== Physicians' concerns about the Marshall Protocol ======
 +
 +<relatedarticle> [[home:starting:physician:reluctant#specific_research|Section  to print off - Independant research into Olmesartan with PMIDs for doctor.]] </article>
  
 Over the years, physicians have voiced various concerns about the Marshall Protocol, concerns ranging from the safety of higher doses of olmesartan (Benicar) to concerns about long-term antibiotic use. The Autoimmunity Research Foundation has assembled articles, well-grounded in scientific research, which address these concerns. Physicians who choose to use and administer the MP do so on the basis of the [[home:physicians:concerns#concerns_about_lack_of_clinical_evidence|available evidence]]. Over the years, physicians have voiced various concerns about the Marshall Protocol, concerns ranging from the safety of higher doses of olmesartan (Benicar) to concerns about long-term antibiotic use. The Autoimmunity Research Foundation has assembled articles, well-grounded in scientific research, which address these concerns. Physicians who choose to use and administer the MP do so on the basis of the [[home:physicians:concerns#concerns_about_lack_of_clinical_evidence|available evidence]].
Line 5: Line 7:
 ===== Concerns about lack of clinical evidence ===== ===== Concerns about lack of clinical evidence =====
  
-  - **"There are no well-controlled studies to support the use of the Marshall Protocol for a given indication."** This statement is accurate. As of 2012, patients and physicians who choose to use and administer the MP do so based on the following evidence:+  - **"There are no well-controlled studies to support the use of the Marshall Protocol for a given indication."** This statement is accurate. In 2012, patients and physicians who chose to use and administer the MP did so based on the following evidence:
     * a [[home:publications:proal_molecular_2011|2011 case series of MP patients]] appearing in the (Nature Publishing Group) journal //Clinical & molecular immunology//     * a [[home:publications:proal_molecular_2011|2011 case series of MP patients]] appearing in the (Nature Publishing Group) journal //Clinical & molecular immunology//
     * a [[home:publications:mp2008_survey|2008 retrospective survey]] of 100 MP patients with autoimmune diagnoses     * a [[home:publications:mp2008_survey|2008 retrospective survey]] of 100 MP patients with autoimmune diagnoses
Line 15: Line 17:
  
 For some physicians, the above evidence is not sufficiently compelling to warrant automatically starting a patient on the MP without further consideration. Here are some other factors which may play a role in the clinical judgment: For some physicians, the above evidence is not sufficiently compelling to warrant automatically starting a patient on the MP without further consideration. Here are some other factors which may play a role in the clinical judgment:
-  * evidence for the efficacy of MP versus other available treatment options(({{pubmed>long:19050187}})) +  * alternative hypotheses and evidence of research (({{pubmed>long:    15246025}})), (({{pubmed>long:16403216}})), (({{pubmed>long:23370376}})), (({{pubmed>long:18200565}}))  
-  * more recent material on patient response, see below update+  * evidence for the efficacy of MP versus other available treatment in 2013 data on patient response, see section below 
   * patients' expressed preferences and values(({{pubmed>long:19050187}}))   * patients' expressed preferences and values(({{pubmed>long:19050187}}))
   * additional benefits of Olmesartan [[https://mpkb.org/home/protocol/olmesartan#other_benefits_of_olmesartan_in_patients_-_recent_studies|other researched benefits]]   * additional benefits of Olmesartan [[https://mpkb.org/home/protocol/olmesartan#other_benefits_of_olmesartan_in_patients_-_recent_studies|other researched benefits]]
Line 25: Line 27:
 <html></p></div></html> <html></p></div></html>
  
-===== Numerical improvements update =====+==== Recorded results assessed 2013  ====
  
 <blockquote>//DJ posted// :- During the summer of 2013 I looked at 2,000 records of people using the Marshall Protocol.</blockquote>  <blockquote>//DJ posted// :- During the summer of 2013 I looked at 2,000 records of people using the Marshall Protocol.</blockquote> 
Line 79: Line 81:
  
   - **"A temporary increase in symptoms or laboratory values means the treatment is not working."** – \\ Immunopathology is an increase in one's present symptoms of Th1 inflammation or a return of previous Th1 inflammatory symptoms, that is caused by cytokines and endotoxins being released from dying bacteria. In some cases there may be a temporary experience of symptoms attributable to a previously unexperienced condition. Immunopathology is a necessary part of recovery. The amount of immunopathology a patient experiences on the Marshall Protocol (MP) is correlated with disease severity. Patients who are less sick will have comparatively less strong immunopathology. [[home:protocol:immunopathology|Read more →]]   - **"A temporary increase in symptoms or laboratory values means the treatment is not working."** – \\ Immunopathology is an increase in one's present symptoms of Th1 inflammation or a return of previous Th1 inflammatory symptoms, that is caused by cytokines and endotoxins being released from dying bacteria. In some cases there may be a temporary experience of symptoms attributable to a previously unexperienced condition. Immunopathology is a necessary part of recovery. The amount of immunopathology a patient experiences on the Marshall Protocol (MP) is correlated with disease severity. Patients who are less sick will have comparatively less strong immunopathology. [[home:protocol:immunopathology|Read more →]]
 +
 +see also [[home:protocol:olmesartan:safety#recent_research|research into Enteropathy]] 
  
 ===== Concerns about antibiotics=====  ===== Concerns about antibiotics===== 
Line 104: Line 108:
  
 ==== Read also ==== ==== Read also ====
 +
 +[[http://electromagnetichealth.org/wp-content/uploads/2012/04/EMF-Guideline.pdf|Guideline of the Austrian Medical Association for the diagnosis and treatment of EMF-related health problems and illnesses (EMF syndrome) ]]
  
 **Evaluation of the Effect of Radiofrequency Radiation Emitted From Wi-Fi Router and Mobile Phone Simulator on the Antibacterial Susceptibility of Pathogenic Bacteria Listeria monocytogenes and Escherichia coli.**\\ Altogether, the findings of this study showed that exposure to Wi-Fi and RF simulator radiation can significantly alter the inhibition zone diameters and growth rate for L monocytogenes and E coli. These findings may have implications for the management of serious infectious diseases.  (({{pubmed>long:28203122}})) **Evaluation of the Effect of Radiofrequency Radiation Emitted From Wi-Fi Router and Mobile Phone Simulator on the Antibacterial Susceptibility of Pathogenic Bacteria Listeria monocytogenes and Escherichia coli.**\\ Altogether, the findings of this study showed that exposure to Wi-Fi and RF simulator radiation can significantly alter the inhibition zone diameters and growth rate for L monocytogenes and E coli. These findings may have implications for the management of serious infectious diseases.  (({{pubmed>long:28203122}}))
Line 111: Line 117:
  
  
-{{tag>resources_for_physicians}}+{{tag>resources_for_physicians research}} 
 + 
 +[[home:starting:physician:reluctant#Specific_research|Section  to print off - Independent research into Olmesartan with PMIDs for doctor.]]
 ===== Notes and comments ===== ===== Notes and comments =====
  
home/physicians/concerns.txt · Last modified: 09.14.2022 by 127.0.0.1
© 2015, Autoimmunity Research Foundation. All Rights Reserved.